Larazotide acetate
Also called AT-1001
- Evidence
- Limited research
- Class
- Zonulin antagonist (tight-junction regulator)
Larazotide acetate belongs to the Zonulin antagonist (tight-junction regulator) class. This library groups it under digestive & weight. Its source category is In clinical trials.
At a glance
| Compound class | Zonulin antagonist (tight-junction regulator) |
|---|---|
| Body system | Digestive & weight |
| Use or research focus | Celiac disease (adjunct) |
| Regulatory status | Investigational (Phase 3 missed endpoint) |
| Source evidence rating | Limited research |
How does Larazotide acetate work?
Reduces intestinal permeability.
The source catalog maps this mechanism to Gut / GI. A biological mechanism describes how a compound interacts with the body; it does not by itself prove a clinical benefit.
What does the evidence tell us?
The source catalog rates the evidence as limited. Laboratory and animal findings cannot establish benefits or safety in people. Small or early studies may raise useful research questions without supporting routine clinical use.
Use the Citations tab to examine the underlying sources. Look for human studies, a relevant comparison group, meaningful outcomes, and adequate follow-up. An ingredient, approved drug, and compounded preparation may have different evidence.
Safety and considerations
A compound being studied in a clinical trial is not necessarily approved or effective. Trial participants follow a study protocol with eligibility criteria and monitoring. Results from one population or formulation may not apply to another.
This library is educational and does not provide dosing or treatment instructions. A listing here does not indicate that Peppy offers the compound.
Common questions
What is Larazotide acetate?
Larazotide acetate belongs to the Zonulin antagonist (tight-junction regulator) class. This library groups it under digestive & weight. Its source category is In clinical trials. Its recorded use or research focus is: Celiac disease (adjunct).
Is Larazotide acetate FDA-approved?
The catalog records: Investigational (Phase 3 missed endpoint). Check the current product-specific regulatory information in the source links; a source category does not establish approval for every use or formulation.
How strong is the research?
The source catalog rates the evidence as limited. Laboratory and animal findings cannot establish benefits or safety in people. Small or early studies may raise useful research questions without supporting routine clinical use.
Where can I read the research?
The Citations tab contains 3 reference links from the source dataset. The original research guide provides additional context. These links are a starting point for reading the evidence.
More for digestive & weight
Factual catalog fields and citation links are adapted from Superpower’s Larazotide acetate guide and the public dataset linked in the reference post. Peppy’s explanations are educational; this page does not represent an independent clinical review of every linked study.
Sources & further reading
References associated with Larazotide acetate in the source dataset. Open a source to review its study design, population, limitations, and date.
View the original research guide